- |||||||||| Journal: Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0. (Pubmed Central) - Jul 3, 2024
IgA3.0 matuzumab exhibited reduced receptor internalization compared to the other antibodies, possibly accounting for its superior in vivo Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Molecular pathways and targeted therapies in head and neck cancers pathogenesis. (Pubmed Central) - Jul 2, 2024
Initiatives to engineer therapies targeting these dysregulated pathways are underway, with several candidate molecules progressing to clinical evaluation phases, including FDA approval for agents like the EGFR-targeting monoclonal antibody cetuximab for K-RAS wild-type, EGFR-mutant HNSCC treatment...Enhanced comprehension of the genomic and immunological landscapes characteristic of HNC is anticipated to facilitate a more rigorous assessment of targeted therapies benefits and limitations, optimize their clinical deployment, and foster innovative advancements in treatment approaches. This review presents an update on the molecular mechanisms and mutational spectrum of HNC driving the oncogenesis of head and neck malignancies and explores their implications for advancing diagnostic methodologies and precision therapeutics.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Electrolyte disorders in oncological patients (Pubmed Central) - Jul 1, 2024
Hypomagnesemia is often iatrogenic, related to cisplatin or cetuximab, but can be prevented by supplementation...Prevention and early diagnosis of ED are essential to optimize the overall management of patients with underlying cancer and cancer therapy. The aim of this review is to synthesize most frequent ED and their management.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. (Pubmed Central) - Jul 1, 2024
In this study, we developed an EGFR-targeting immunotoxin consisting of a clinically proven anti-EGFR IgG (cetuximab; CTX) and a toxin fragment (LR-LO10) derived from Pseudomonas exotoxin A (PE) using a novel site-specific conjugation technology (peptide-directed photo-crosslinking reaction), as an alternative option...Transcriptome analyses revealed that the immunotoxins elicited immune responses and altered the expression of genes related to its mechanisms of action. These results support the notion that CTX-LR-LO10 may serve as a new therapeutic agent targeting EGFR-positive cancers.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer (clinicaltrials.gov) - Jun 28, 2024
P=N/A, N=46, Completed,
These results support the notion that CTX-LR-LO10 may serve as a new therapeutic agent targeting EGFR-positive cancers. Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2025 --> Nov 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: An Efficient Method for Vault Nanoparticle Conjugation with Finely Adjustable Amounts of Antibodies and Small Molecules. (Pubmed Central) - Jun 27, 2024
Thus, we could demonstrate antibody-dependent, selective uptake by the SKBR3 and MDA-MB 231 breast cancer cell lines. These investigations provide a novel, flexible technological platform that significantly extends vault-Z's applications, in that it can be stably conjugated with finely adjusted amounts of antibodies as well as of other molecules, such as fluorophores, cell-targeting peptides, or drugs, using the Fc portion as a scaffold.
- |||||||||| BMS-986315 / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 26, 2024
P1/2, N=308, Active, not recruiting,
These investigations provide a novel, flexible technological platform that significantly extends vault-Z's applications, in that it can be stably conjugated with finely adjusted amounts of antibodies as well as of other molecules, such as fluorophores, cell-targeting peptides, or drugs, using the Fc portion as a scaffold. Trial primary completion date: Apr 2024 --> Aug 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas. (Pubmed Central) - Jun 26, 2024
Herein, we explore the cellular mechanisms of resistance reported in HNSCC, including those related to epigenetic factors, DNA repair defects, and several signaling pathways. This article discusses these mechanisms and possible approaches that can be used to target different pathways to sensitize HNSCC to the existing treatments, obtain better responses to new agents, and ultimately improve the patient outcomes.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer. (Pubmed Central) - Jun 18, 2024
Therefore, presentation of AREG on Rab11a-exosomes affects its ability to compete with cetuximab. We propose that this Rab11a-exosome-mediated mechanism contributes to the establishment of resistance in cetuximab-sensitive cells and may explain why in cetuximab-resistant tumours only some cells carry mutant KRAS.
- |||||||||| CIML NK - Dana / Farber Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Jun 16, 2024
P1, N=25, Recruiting,
We propose that this Rab11a-exosome-mediated mechanism contributes to the establishment of resistance in cetuximab-sensitive cells and may explain why in cetuximab-resistant tumours only some cells carry mutant KRAS. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab. (Pubmed Central) - Jun 13, 2024
The patient initially responded well, but his disease progressed 2 months later. Further research is needed to improve management strategies for BRAF V600E-mutated colorectal cancer with CNS metastases.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Journal: EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. (Pubmed Central) - Jun 10, 2024
Likewise, patient-derived organoids (PDOs) from individuals with ER+ mBC, progressing on palbociclib, exhibited up-regulation of EGFR and HER2 pathways. In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET+CDK4/6i in selected patients with ER+ mBC.
- |||||||||| ZEN-3694 / Zenith Capital Corp, Erbitux (cetuximab) / Eli Lilly, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial initiation date, Combination therapy, Metastases: Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (clinicaltrials.gov) - Jun 9, 2024
P1, N=30, Recruiting,
In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET+CDK4/6i in selected patients with ER+ mBC. Initiation date: Nov 2024 --> Jun 2024
- |||||||||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Tumor cell: Combining SiRP? decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. (Pubmed Central) - Jun 3, 2024
Moreover, avelumab and cetuximab enhanced macrophage-mediated phagocytosis of tumor cells in vitro in the presence of CV1 and improved tumor control upon coadministration with A97L-T cells. Taken together, our study indicates important clinical promise for harnessing macrophages by combining CV1-coengineered TCR-T cells with targeted antibodies to direct phagocytosis against tumor cells.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal, Metastases: Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. (Pubmed Central) - Jun 2, 2024
P2
Taken together, our study indicates important clinical promise for harnessing macrophages by combining CV1-coengineered TCR-T cells with targeted antibodies to direct phagocytosis against tumor cells. The study met its primary objectives on objective response and morbidity, and showed overall survival to be as good as in younger patients treated with standard regimens, indicating that the adapted EXTREME regimen could be used in older patients with recurrent or metastatic HNSCC who are deemed fit with use of a geriatric evaluation tool adapted to patients with head and neck cancer, such as the EGE.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Metastases: Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. (Pubmed Central) - Jun 2, 2024
The study met its primary objectives on objective response and morbidity, and showed overall survival to be as good as in younger patients treated with standard regimens, indicating that the adapted EXTREME regimen could be used in older patients with recurrent or metastatic HNSCC who are deemed fit with use of a geriatric evaluation tool adapted to patients with head and neck cancer, such as the EGE. The efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC were consistent with those reported in the BEACON CRC trial, supporting its use as a standard treatment for pretreated patients with BRAFV600E-mutant mCRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Exosomal circPVT1 promotes angiogenesis in laryngeal cancer by activating the Rap1b-VEGFR2 signaling pathway. (Pubmed Central) - Jun 2, 2024
Furthermore, our xenograft models demonstrated that the combination of shRNA-circPVT1 and cetuximab showed high efficacy in inhibiting tumor growth and angiogenesis. Collectively, these findings uncover a novel mechanism of exosomal circular RNA-mediated angiogenesis modulation and provide a preclinical rationale for testing this analogous combination in patients with LC.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
Clinical outcomes of advanced head and neck cancer patients treated with immune checkpoint inhibitors at Mount Vernon Cancer Centre (Mezzanine level of the exhibition area) - May 17, 2024 - Abstract #BAHNO2024BAHNO_44;
This study showed an overall survival (OS) benefit versus the standard EXTREME cetuximab-chemotherapy combination...The nivolumab cohort had a median PFS of 3.7m (0.7-55.3), with IRT in 41.5%, (n= 17)...Our analysis shows a similar safety profile and patient outcomes to a recent pooled analysis on use of pembrolizumab monotherapy and previously published immune checkpoint inhibitor studies. Pfs pembro data- table.png
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Retrospective data, Journal, Monotherapy, Metastases: Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. (Pubmed Central) - May 17, 2024
Previous therapy with fruquintinib or regorafenib was allowed but not mandatory...Multivariate Cox regression analysis demonstrated that undergoing therapy after TAS-102 either with or without BEV was an independent risk factor for OS [hazard ratio (HR) =0.25; 95% confidence interval (CI): 0.09-0.71, P<0.01], and previous treatment with cetuximab was an independent protective factor for PFS (HR =0.17; 95% CI: 0.03-0.91, P=0.04)...There was a trend in favor of the combination of BEV plus TAS-102 regarding OS and DCR, without reaching statistical significance, and it means that there was no clear advantage of one over the other in terms of efficacy. Further prospective studies are still necessary to draw a definite conclusion.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: The involvement of epidermal growth factor receptor/protein kinase B (Pubmed Central) - May 15, 2024
Further prospective studies are still necessary to draw a definite conclusion. OSCC cells-expressing PD-L1 induced by EGF stimulation may promote malignancy intrinsically via the activation of the EGFR/AKT signaling cascade.
- |||||||||| utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 15, 2024
P1, N=42, Active, not recruiting,
OSCC cells-expressing PD-L1 induced by EGF stimulation may promote malignancy intrinsically via the activation of the EGFR/AKT signaling cascade. Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: SOX18 meditates the resistance of Bmi1-expressing cells to cetuximab in HNSCC. (Pubmed Central) - May 13, 2024
Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026 Taken together, the findings of our study suggest that Sox18 mediates the resistance of Bmi1-expressing cells to cetuximab in HNSCC via the oxidative phosphorylation pathway.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Memory-like differentiation enhances NK cell responses against colorectal cancer. (Pubmed Central) - May 13, 2024
ML NK cells from healthy donors and mCRC patients exhibited increased anti-CRC responses. Collectively, our findings demonstrate that ML NK cells exhibit enhanced responses against CRC targets, warranting further investigation in clinical trials for mCRC patients, including those who have failed ICB.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Gallic Acid Can Promote Low-Density Lipoprotein Uptake in HepG2 Cells via Increasing Low-Density Lipoprotein Receptor Accumulation. (Pubmed Central) - May 11, 2024
When the pathway was inhibited by EGFR mab cetuximab, it was observed that the activation of the EGFR-ERK1/2 signaling pathway induced by GA was also blocked...This ultimately results in increased LDLR protein accumulation and enhanced uptake of LDL in cells. In summary, the present study revealed the potential mechanism of GA's role in ameliorating NAFLD, with a view of providing a theoretical basis for the dietary supplementation of GA.
|
